Phacilitate Leaders Forum

29TH - 30TH SEPTEMBER 2020

ETC BISHOPSGATE LONDON

Speakers

Loading
Marco Ruella

Marco Ruella

Assistant Professor Of Medicine and Scientific Director, University of Pennsylvania

Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally designing combined innovative immunotherapies for relapsing/refractory leukemia and lymphoma. He is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CAR T therapy. His work has been recognized through numerous awards including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), and most recently the 2018 American Society of Hematology Joanne Levy, MD, Memorial Award for Outstanding Achievement. Dr. Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. After completing his fellowship, he was an attending physician in the Hematology and Cell Therapy Division of the Mauriziano Hospital and an instructor at the Biotechnology School at the University of Torino. From 2012, he was a postdoctoral fellow, and then an instructor at the University of Pennsylvania in the Center for Cellular Immunotherapies where he worked with Drs. June and Gill until appointment to his current position in 2018.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd